Holen Sie sich die Stockscreener-App
0.4031
0.47%
0.0019
Handel nachbörslich:
.40
-0.0031
-0.77%
Traws Pharma Inc Aktie (TRAW) Neueste Nachrichten
Traws (TRAW) Shares: Ends Higher by 1.92% at $0.53 in the Current Update; Market Levels: the Price Remains Bounded by the Supplied Support and Resistance in the Latest SessionATR Stop - vinanet.vn
Traws (TRAW) Shares: Ends Higher by 1.92% at $0.53 in the Current Update; Market Levels: the Price Remains Bounded by the Supplied Support and Resistance in the Latest SessionHigh Yield Stocks - siam.in
H.C. Wainwright Maintains Traws Pharma(TRAW.US) With Hold Rating, Maintains Target Price $1 - Moomoo
Traws Pharma Ties Up To $50 Million Of Additional Financing To Influenza Regulatory And Clinical Milestones - Pulse 2.0
TRAW Reiterated by HC Wainwright & Co. -- Maintains Price Target at $1.00 - GuruFocus
H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 - Investing.com
H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 By Investing.com - Investing.com UK
H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 - Investing.com
Traws Pharma (NasdaqCM:TRAW) Stock Forecast & Analyst Predictions - Simply Wall Street
Traws Pharma shares rise after Q2 loss comes in better than expected - Yahoo Finance
Traws Pharma beats Q2 loss estimates, shares jump 4% By Investing.com - Investing.com South Africa
Traws Pharma beats Q2 loss estimates, shares jump 4% By Investing.com - Investing.com Australia
Traws Pharma beats Q2 loss estimates, shares jump 4% - Investing.com
Traws Pharma beats Q2 loss estimates, shares jump 4% By Investing.com - Investing.com UK
Traws Pharma beats Q2 loss estimates, shares jump 4% - Investing.com
TRAW Looks 95.6% Undervalued on GF Value™ Amid Price-to-Sales Co - GuruFocus
Ikarian Capital (TRAW) reports 1.56M-share, 9.5% beneficial stake in Traws Pharma - Stock Titan
Traws Pharma Flags Cash Runway Risk Into Q1 2027 Amid FDA Clinical Hold - Minichart
Traws Pharma prepares MHRA resubmission for influenza study - scanx.trade
Traws Pharma Reports Q2 Results, Influenza Program Advances - TipRanks
Traws Pharma Q2 Results: EPS beats estimate, losses widen 45% YoY - scanx.trade
Traws Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Traws Pharma, Inc. Q2 2026: Revenue $0 EPS $(0.16) — 10-Q Summary - TradingView
TRAW: Net loss increased, cash is insufficient for 12 months, and Nasdaq delisting risk remains high - TradingView
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights - The Manila Times
Traws Pharma Q2 revenue falls to zero on licensing termination; net loss widens - TradingView
Traws Pharma Reports Q2 2026 Net Loss of $3.0 Million - Quiver Quantitative
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights - GlobeNewswire
Traws Pharma (TRAW) investor Squadron reports 0% beneficial ownership in 13G/A - Stock Titan
Sirenia Capital (TRAW) discloses warrant-based stake capped at 9.9% ownership - Stock Titan
Adage Capital reports 4.79% Traws Pharma (TRAW) stake totaling 730,000 shares - Stock Titan
Traws Pharma Q1 2026 Earnings: Net Loss Narrows Sharply, EPS Beats Consensus by 29.78%Analyst Earnings Estimate - dars.gov.et
Traws Pharma Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Traws Pharma Inc (TRAW) Stock News Today - TradingKey
Traws Pharma Inc (NASDAQ: TRAW) Share Price, TRAW Stock News, TRAW Share Price & Updates - Kalkine
Traws Pharma Inc (TRAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
TRAW Q1 2026 Earnings: Loss Narrows 29.8% Versus Estimates as Pre-Revenue Biotech Holds CourseEPS Consistency Score - vinanet.vn
TRAW Q2'26 Earnings: EPS estimate is (0.34) USD - TradingView
TRAW Moves TRX-100 Through Early Human Testing: What Investors Should Watch - tipranks.com
Traws Pharma, Inc. Files Form 8-K: Company Details, NASDAQ Listing, and Compliance Information (July 2026) - Minichart
Traws Pharma Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
Traws Pharma, Inc. Revenue Breakdown – NASDAQ:TRAW - TradingView
Traws Pharma Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Investor SentimentROIC Trend Report - dars.gov.et
Traws Pharma Receives Nasdaq Minimum Bid Price Notice - TipRanks
Traws Pharma Received Notice of Noncompliance - TradingView
Traws Pharma (TRAW) Edges Higher: Micro-Cap Biotech Defends $0.43 SupportHead and Shoulders - vinanet.vn
TRAW Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Traws Pharma Inc (TRAW) Balance Sheet - TradingKey
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):